EP3897579A4 - COMPOSITIONS, DEVICES AND METHODS FOR TREATING OVERDOSE AND REWARD-RELATED DISORDERS - Google Patents

COMPOSITIONS, DEVICES AND METHODS FOR TREATING OVERDOSE AND REWARD-RELATED DISORDERS Download PDF

Info

Publication number
EP3897579A4
EP3897579A4 EP19898164.9A EP19898164A EP3897579A4 EP 3897579 A4 EP3897579 A4 EP 3897579A4 EP 19898164 A EP19898164 A EP 19898164A EP 3897579 A4 EP3897579 A4 EP 3897579A4
Authority
EP
European Patent Office
Prior art keywords
overdose
reward
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19898164.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3897579A1 (en
Inventor
Edward T. Maggio
Roger CRYSTAL
Mark ELLISON
Phil Skolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indivior UK Ltd
Aegis Therapeutics LLC
Original Assignee
Aegis Therapeutics LLC
Opiant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegis Therapeutics LLC, Opiant Pharmaceuticals Inc filed Critical Aegis Therapeutics LLC
Publication of EP3897579A1 publication Critical patent/EP3897579A1/en
Publication of EP3897579A4 publication Critical patent/EP3897579A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19898164.9A 2018-12-20 2019-12-19 COMPOSITIONS, DEVICES AND METHODS FOR TREATING OVERDOSE AND REWARD-RELATED DISORDERS Pending EP3897579A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201816311944A 2018-12-20 2018-12-20
US201862782943P 2018-12-20 2018-12-20
PCT/US2019/067513 WO2020132263A1 (en) 2018-12-20 2019-12-19 Compositions, devices, and methods for the treatment of overdose and reward-based disorders

Publications (2)

Publication Number Publication Date
EP3897579A1 EP3897579A1 (en) 2021-10-27
EP3897579A4 true EP3897579A4 (en) 2022-11-16

Family

ID=71100913

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19898164.9A Pending EP3897579A4 (en) 2018-12-20 2019-12-19 COMPOSITIONS, DEVICES AND METHODS FOR TREATING OVERDOSE AND REWARD-RELATED DISORDERS

Country Status (10)

Country Link
EP (1) EP3897579A4 (es)
JP (1) JP2022514340A (es)
KR (1) KR20210131996A (es)
CN (1) CN113573696A (es)
AU (1) AU2019403368A1 (es)
CA (1) CA3124202A1 (es)
IL (1) IL284117A (es)
MX (1) MX2021007522A (es)
SG (1) SG11202106531VA (es)
WO (1) WO2020132263A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3044221A1 (en) 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Intranasal nalmefene compositions and methods for the treatment of opioid overdose

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223566A1 (en) * 2016-06-24 2017-12-28 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of alcohol use disorder
WO2018089709A1 (en) * 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
US20140171458A1 (en) * 2012-12-13 2014-06-19 3B Pharmaceuticals, Inc. Intranasal naltrexone
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223566A1 (en) * 2016-06-24 2017-12-28 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of alcohol use disorder
WO2018089709A1 (en) * 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020132263A1 *

Also Published As

Publication number Publication date
CN113573696A (zh) 2021-10-29
CA3124202A1 (en) 2020-06-25
SG11202106531VA (en) 2021-07-29
KR20210131996A (ko) 2021-11-03
JP2022514340A (ja) 2022-02-10
WO2020132263A1 (en) 2020-06-25
IL284117A (en) 2021-08-31
AU2019403368A1 (en) 2021-07-29
MX2021007522A (es) 2021-08-05
EP3897579A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
EP3675882A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3570844A4 (en) AZOLOPYRIMIDINE FOR TREATING CANCER-BASED DISEASES
EP3801758A4 (en) SYSTEMS, DEVICES AND METHODS FOR THE TREATMENT OF ORO-PHARYNGEAL DISORDERS
EP3746135A4 (en) METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
EP3618829A4 (en) QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER ASSOCIATED DISORDERS
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
EP3490603A4 (en) MASP-3 INHIBITION COMPOSITIONS AND METHODS FOR THE TREATMENT OF MISCELLANEOUS DISEASES AND CONDITIONS
EP3634417A4 (en) QUINAZOLINE-PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
EP3890748A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
EP3538189A4 (en) COMPOSITIONS, DEVICES AND METHODS FOR TREATING OPIOID RECEPTOR-MEDIATED STATES
EP3684418A4 (en) TREATMENT METHODS FOR CYSTEAMINE SENSITIVE CONDITIONS
EP3558279A4 (en) COMPOSITIONS AND PROCEDURES FOR TREATMENT OF CHRONIC PAIN
EP3352749A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
EP3651747A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISORDERS
EP3566055A4 (en) TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
EP3810777A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS
EP3856169A4 (en) Methods of treating myeloproliferative disorders
EP3755319A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES
EP3310358A4 (en) COMPOSITIONS AND METHODS FOR TREATING SUBSTANCE ABUSE, SEARCH AND PSYCHIATRIC DISORDER
EP3661502A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES
EP3600324A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
EP4010347A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN AND DEPENDENCY DISEASES
EP3856147A4 (en) PROBIOTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE LESIONS
EP3846851A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISORDERS OF THE LYMPHATIC SYSTEM
IL284117A (en) Preparations, devices and methods for the treatment of disorders based on overdose and compensation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210624

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40055520

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221017

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 11/00 20060101ALI20221011BHEP

Ipc: A61M 15/00 20060101ALI20221011BHEP

Ipc: A61K 38/00 20060101ALI20221011BHEP

Ipc: A61K 31/485 20060101ALI20221011BHEP

Ipc: A61K 31/496 20060101ALI20221011BHEP

Ipc: A61K 31/4178 20060101ALI20221011BHEP

Ipc: A61K 31/357 20060101ALI20221011BHEP

Ipc: A61P 1/00 20060101ALI20221011BHEP

Ipc: A61K 9/20 20060101ALI20221011BHEP

Ipc: A61K 47/26 20060101ALI20221011BHEP

Ipc: A61K 47/18 20170101ALI20221011BHEP

Ipc: A61K 9/00 20060101AFI20221011BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INDIVIOR UK LIMITED

Owner name: AEGIS THERAPEUTICS, LLC